Revenue
No reported data
Mineralys Therapeutics, Inc. (MLYS)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Research & development | $132.0M | $168.6M | $70.4M | $26.3M |
| Operating expenses | $170.6M | $192.4M | $84.7M | $31.5M |
| Operating income | −$170.6M | −$192.4M | −$84.7M | −$31.5M |
| EBITDAderived | −$170.5M | −$192.4M | −$84.7M | — |
| Net income | −$154.7M | −$177.8M | −$71.9M | −$29.8M |
| Basic EPSper diluted share | -$2.29 | -$3.66 | -$1.99 | -$5.77 |
| Diluted EPSper diluted share | -$2.29 | -$3.66 | -$1.99 | -$5.77 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 30, 2026Form 4 · 10b5-1 | Congleton JonChief Executive Officer | SellCommon Stock | 17.0K | $26.82 | $455.9K | 614.3K |
| Jun 30, 2026Form 4 · 10b5-1 | Congleton JonChief Executive Officer | SellCommon Stock | 58.0K | $25.94 | $1.50M | 631.3K |
| Jun 26, 2026Form 4 · 10b5-1 | Warren EricChief Commercial Officer | SellCommon Stock | 104.1K | $25.90 | $2.70M | 38.4K |
| Jun 17, 2026Form 4 · 10b5-1 | Rodman David MalcomChief Medical Officer | SellCommon Stock | 4.6K | $25.00 | $114.6K | 57.1K |
| Jun 17, 2026Form 4 · 10b5-1 | Karydas DaphneDirector | SellCommon Stock | 3.0K | $25.00 | $75.0K | 6.2K |